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Abstract
Background: Lung adenocarcinoma is the leading cause of cancer-related deaths among both men and women in the
world. Despite recent advances in diagnosis and treatment, the mortality rates with an overall 5-year survival of only 15%.
This high mortality is probably attributable to early metastasis. Although several well-known markers correlated with poor/
metastasis prognosis in lung adenocarcinoma patients by immunohistochemistry was reported, the molecular mechanisms
of lung adenocarcinoma development are still not clear. To explore novel molecular markers and their signaling pathways
will be crucial for aiding in treatment of lung adenocarcinoma patients.
Methodology/Principal Findings: To identify novel lung adenocarcinoma-associated /metastasis genes and to clarify the
underlying molecular mechanisms of these targets in lung cancer progression, we created a bioinformatics scheme
consisting of integrating three gene expression profile datasets, including pairwise lung adenocarcinoma, secondary
metastatic tumors vs. benign tumors, and a series of invasive cell lines. Among the novel targets identified, FLJ10540 was
overexpressed in lung cancer tissues and is associated with cell migration and invasion. Furthermore, we employed two co-
expression strategies to identify in which pathway FLJ10540 was involved. Lung adenocarcinoma array profiles and tissue
microarray IHC staining data showed that FLJ10540 and VEGF-A, as well as FLJ10540 and phospho-AKT exhibit positive
correlations, respectively. Stimulation of lung cancer cells with VEGF-A results in an increase in FLJ10540 protein expression
and enhances complex formation with PI3K. Treatment with VEGFR2 and PI3K inhibitors affects cell migration and invasion
by activating the PI3K/AKT pathway. Moreover, knockdown of FLJ10540 destabilizes formation of the P110-a/P85-a-(PI3K)
complex, further supporting the participation of FLJ10540 in the VEGF-A/PI3K/AKT pathway.
Conclusions/Significance: This finding set the stage for further testing of FLJ10540 as a new therapeutic target for treating
lung cancer and may contribute to the development of new therapeutic strategies that are able to block the PI3K/AKT
pathway in lung cancer cells.
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Introduction
Lung cancer is the leading cause of cancer-related deaths
among both men and women in the world [1–2]. Despite recent
advances in diagnosis and treatment, the mortality rates remain
high, with an overall 5-year survival of only 15%. Surgery remains
the first choice of treatment for localized non-small cell lung
cancer and provides the best opportunity for cure. However, when
first diagnosed, most patients already have advanced disease, and
only 35% of patients with non-small cell lung cancer (NSCLC) are
eligible for resection [3]. Novel molecular markers or targets
aiding in diagnosis and treatment will be crucial for improving the
mortality rate.
Tumor invasion and metastasis are important areas for study in
order to determine the aggressive phenotype of human cancers
and are the major causes of cancer deaths [4]. The process of
metastasis is very complex and is considered a late event in
tumorigenesis, i.e. cells proliferate, lose contact with neighboring
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5052cells, migrate through the interstitial matrix, invade blood and
lymph vessels, and deposit into the lymph nodes. Migration and
invasion of cells appear to be a result of a complex interplay
between the numerous protein families that participate in this
process. Mechanisms of cell movement are important not only as
part of basic cellular and developmental processes, but also in the
pathogenesis of various diseases [5]. To become metastatic, tumor
cells must increase the expression of various metastasis-promoting
genes. However, in lung cancer, the molecules and mechanisms
involved in cell migration or invasion remain largely unknown.
Production and secretion of VEGF-A is commonly observed in
most aggressive tumors, and expression of VEGF-A profoundly
influences the prognosis of cancer patients, including those with
lung cancer [6–8]. VEGF-A is one of the most potent stimulators
of angiogenesis identified thus far, affecting endothelial cell
vascular permeability, proliferation, and motility [7]. Although
various intracellular signaling pathways have been proposed to
mediate the biological activities of VEGF-A in endothelial cells,
the signaling events involved in cell migration and invasion in
response to VEGF-A stimulation in lung cancer are not fully
understood.
FLJ10540 has several names, including CEP55 [9], C10orf3
[10], and URCC6. CEP55 tagged with GFP-C localizes to the
centrosome in interphase cells, to the spindle midzone during
anaphase, and to the midbody during cytokinesis [9,11–12].
Furthermore, Cdk1, ERK2, and Plk1 cooperate in the phosphor-
ylation of CEP55 during mitosis, which is required for the correct
mitotic localization of CEP55 and its function during cytokinesis
[9]. FLJ10540 is overexpressed during human colon [10] and
hepatocellular carcinoma [13] tumorigenesis, suggesting that it
may function as an oncogene in tumor development. In addition,
we previously showed that the overexpression of FLJ10540
contributes to cellular transformation through the activation of
PI3K/AKT [13]. However, no large-scale analysis of FLJ10540
expression and its clinicopathologic and functional significance in
human lung cancer has been performed.
The aggressive behavior of malignant cancer cells is determined
by a complex array of signaling pathways that regulate key
functions, such as growth, survival, migration, and invasion. The
PI3K/AKT signaling pathway has been causally linked to all four
of these responses. [14–17]. Further evidence of the importance of
PI3K/AKT signaling in cancer comes from studies which have
detected overexpression and hyperactivation of PI3K/AKT in a
wide range of human tumors, including lung cancer, and this is
often linked with poor prognosis [18]. Accumulating evidence
from previous reports suggests a potential role of PI3K/AKT in
migration and invasion of various cell types, including lung cancer
[19], liver cancer [20], breast cancer [21], and pancreatic cancer
[22].
In this study, we show that FLJ10540 is overexpressed in lung
adenocarcinoma and that ectopic expression of FLJ10540
promotes cell migration and invasion. In human lung adenocar-
cinoma samples, FLJ10540 positively correlated with VEGF-A
expression, as determined by gene expression profiling and IHC
staining of tissue microarrays. In addition, stimulation with VEGF-
A resulted in an increase in FLJ10540 protein expression in a dose-
dependent manner in CL1-0 lung cancer cells. Furthermore,
FLJ10540 partially translocates from the cytoplasm to the plasma
membrane and enhances complex formation with PI3K under
VEGF-A stimulation. Finally, VEGF-A affects cell migration and
invasion by activating the FLJ10540/PI3K/AKT pathway. These
findings suggest that FLJ10540 overexpression is associated with
an enhanced metastatic potential and may serve as a potential new
therapeutic target for lung adenocarcinoma.
Results
Elevated FLJ10540 expression in lung adenocarcinomas
and invasive lung cancer cell lines
A significant challenge in the post-genomic era is determining
how to prioritize differentially expressed and poorly characterized
targets in cancer-related microarray profiling studies. Here, we set
up a bioinformatics platform by integrating three different
microarray datasets to reveal key regulators involved in the
metastasis of lung cancer. Figure 1 shows the schematic data
integration approaches and FLJ10540 expression data in different
categories. First, samples from 26 patients with lung adenocarci-
noma, confirmed by histopathology, were subjected to Affymetrix
microarray profiling. Based on the 26 primary lung adenocarci-
noma specimens, 826 out of 22,283 differentially expressed
transcripts between adjacent non-tumor and tumor areas were
clustered by the Wilcoxon signed rank test (p,0.01), based on two-
fold differences and tested using the Benjamini and Hochberg false
discovery rate correlation (p,0.01). These molecular portraits,
containing 192 up-regulated and 634 down-regulated transcripts,
could successfully distinguish the patients’ adjacent non-tumor and
tumor areas by hierarchical clustering (Figure S1A). Second,
public accessible microarray data (downloaded from GEO) were
used to acquire different microarray datasets, which were
normalized by Quantile Normalization using R to set up potential
a metastatic biomarker identification platform. We compared 225
secondary metastatic tumors (including 20 tumor metastases to the
lymph node and 200 metastatic tumors) and 30 benign tumors to
obtain sets of potential metastatic oncogenes (871) and metastatic
suppressor genes (1042). Finally, to prioritize the targets and to
validate our metastasis-related genes in cell lines, a series of lung
adenocarcinomacell lines, including CL1-0,C L 1-1,C L 1-5 and CL1-5-
F4, with increasing degrees of invasiveness [23], was also subjected
to microarray profiling. A total of 6,238 transcripts had higher
expression levels in the high invasion ability cell line CL1-5-F4 than
the parental CL1-0 cells. The intersection of these three datasets
reveals many novel targets. We characterized the genes that are
conserved only in vertebrates, but not in invertebrates, to reveal
some novel human cancer-specific abnormalities. As a result, we
focused on the poorly characterized gene FLJ10540.
FLJ10540 exhibits up-regulated expression patterns in lung
adenocarcinomas (Figure 1A, left panel) and metastatic signatures
(Figure 1B). To validate the gene expression profiling data for
FLJ10540, Q-RT-PCR was performed on 16-pairwise lung
adenocarcinoma tumor and adjacent non-tumor samples. Figure
S1B shows that overexpression of FLJ10540 was observable in our
lung patient samples, with 15 out of 16 lung patient tumors (94%)
showing a higher signal after normalization to GAPDH for equal
template loading. The average expression level of FLJ10540 in lung
adenocarcinomas was 8 fold higher than that in adjacent non-tumor
lung tissue samples, as analyzed by boxplot (Figure 1A, right panel).
We next verified the expression of FLJ10540 in representative and
freshly frozen lung adenocarcinoma and adjacent non-tumor
samples by immunohistochemistry staining using anti-human
FLJ10540 antibodies. Our data indicate that the level of FLJ10540
was increased in the tumor samples, as compared to that in the
adjacent non-tumor tissues (data not shown).
Expression of FLJ10540 in a series of invasive human lung
adenocarcinoma cancer cell lines
During lung tumor development, one of the most critical
transitions is the progression from in situ to invasive carcinoma. To
explore the possible role of FLJ10540 in the invasiveness of lung
adenocarcinomacells,wefirst examined the expression ofFLJ10540
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either low or high invasive abilities, as previously described [23] by
Q-RT-PCR. The data indicated that levels of FLJ10540 mRNA
were high in CL1-5 and CL1-5-F4 cells that have high invasive and
metastatic abilities, but were lower in the low invasive CL1-0 cells
(Figure 1C, left panel). FLJ10540 protein levels were also markedly
Figure 1. FLJ10540 exhibits differentially expressed patterns in lung adenocarcinomas, metastatic tumors, and a series of human
lung invasive cancer cell lines. (CL1-0,C L 1-1,C L 1-5, and CL1-5-F4, in the order of increasing invasive activity). (A, left panel) The
microarray expression patterns of FLJ10540 in lung adenocarcinoma patients were normalized against the expression patterns on HG_U133A chips. N:
adjacent non-tumor tissues; T: tumor tissues. The boxplot shows the data distribution as a grouping classification and indicates that there is a
statistically significant difference (p,0.0001) between the tumor tissues and the adjacent nont-umor tissues from the same lung cancer patient. (A,
right panel) The mRNA levels of FLJ10540 in samples from 16 lung cancer patients were determined by Q-RT-PCR. The results were normalized against
the expression levels of GAPDH mRNA in each paired sample and plotted with boxplot. (B) The microarray expression patterns of FLJ10540 were
compared among 30 benign tumors, 20 tumor metastases to the lymph node, and 200 metastatic tumors, and were showed with boxplot. (C, left
panel) The mRNA levels of FLJ10540 were determined by Q-RT-PCR in lung cancer cell lines. The results were normalized against the level of GAPDH
mRNA in each cell line. The experiments were performed in triplicate. (C, right panel) Total protein was extracted from CL1-0 and CL1-5-F4 cells and
subjected to immunoblot analysis with anti-FLJ10540. b-actin was used an internal loading control.
doi:10.1371/journal.pone.0005052.g001
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0 cells, as shown by western blot analysis (Figure 1C, right panel).
The results indicated that the upregulation of FLJ10540 mRNA and
protein expression was positively correlated with the invasive
capability of the lung cancer cells, raising the possibility that
upregulation of FLJ10540 might lead to some of the abnormalities
found in human lung adenocarcinoma.
Overexpression of FLJ10540 promotes cell migration and
invasion
Since FLJ10540 is overexpressed in lung adenocarcinoma and a
highly invasive lung cancer cell line, it seemed possible that its
expression might affect cell motility. To clarify role of FLJ10540 in
motility in the mammalian cells, we examined whether overex-
pression of FLJ10540 was able to affect cell migration and
invasion. Two different cell types were employed to evaluate this
possibility. First, CL1-0 cells stably expressing hemagglutinin (HA)-
tagged FLJ10540 were established. Several stable transfectants
with increasing levels of the FLJ10540 protein were selected
(Figure 2A, left panel) for further studies. Interestingly, FLJ10540
overexpression in CL1-0 cells was associated with strikingly altered
cell morphology. FLJ10540 overexpressed clones were decreased
in cell size and appeared to be more spindle-shaped and had
increased intercellular separation compared to vehicle control
clones, which were round-shaped (Figure 2A, middle panel).
However, the proliferation rate, as determined by the MTT assay,
was not significantly different from that of the vehicle control or
cells expressing FLJ10540 during 24 hours (Figure 2A, right
panel). To examine the effect of FLJ10540 on human lung cancer
cell migration, stable cell lines expressing HA-FLJ10540 or vehicle
control were seeded on Transwell chambers. The results showed
that FLJ10540 CL1-0-stable transfectants could increase their
migration, as measured by the Transwell migration assay; this was
compared to the vehicle control, where very few cells migrated
(Figure 2B, left upper panel). Quantitatively speaking, the
migration ability of FLJ10540 CL1-0-stable transfectants was
approximately 6–7 fold higher than that of the vehicle control
(Figure 2B, right upper panel). We next carried out an in vitro
invasion assay using a Matrigel coated barrier filter. After a
24 hour incubation in a Matrigel-coated Transwell chamber,
FLJ10540 CL1-0-stable transfectants had invaded the basement
membrane material and passed through the pores to reach the
underside of the filter (Figure 2B, left bottom panel). Similarly,
FLJ10540 CL1-0 expressing cells showed a 10–12 fold higher
invasion ability than the vehicle control cells (Figure 2B, right
bottom panel).
Second, to avoid clonal effects, a retroviral-based Flag-tagged
FLJ10540 was infected into an RK3E cell line (Figure S2A) that
had previously been used successfully to evaluate migration or
invasion induced by different genes and signaling pathways, such
as fibroblast growth factor 9 (FGF9) [24], k-ras [25], and Snail
Figure 2. FLJ10540 overexpression promotes lung cancer cell migration and invasion. (A, left panel) HA-tagged-FLJ10540 stable clones of
CL1-0 cells were established. The cell lysates were subjected to immunoblot analysis with anti-HA antibody. (A, middle panel) Phase-contrast images
of monolayer cultures of CL1-0 cells expressing FLJ10540 and vehicle control were shown. (A, right panel) To measure cell growth rates, 5610
3 cells of
vehicle-CL1-0 and CL1-0-FLJ10540 stable clones were plated at day 0 in 96-well plates with 10% FBS. The cells were counted at indicated time points by
the MTT assay (OD570) to quantify the cell growth. Data were normalized against the OD570 value on day 0. The growth rate of CL1-0 cells is shown as
the mean6s.d. of three independent experiments. (B, upper panel) For the migration assay, 5610
3 cells of vehicle-CL1-0 and CL1-0-FLJ10540 stable
clones were seeded into the top of a Transwell insert. After 24 hours, the cells on the topside were scraped, and the cells that migrated to the bottom
were fixed and stained with Giemsa. The migration relative-fold of vehicle-CL1-0 and CL1-0-FLJ10540 stable clones was normalized with vehicle control
and presented diagrammatically. (B, bottom panel) For the invasion assay, 1610
4 cells were seeded after Matrigel was added. The invasion relative-
fold of stable clone was normalized against vehicle cells and represented diagrammatically. All of the data represent the mean6s.d. of three
independent experiments.
doi:10.1371/journal.pone.0005052.g002
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near-normal karyotype and a low background of cell migration
and invasion. Mixed pools of infected RK3E cells were used for
the migration and invasion assays. Again, FLJ10540 expressing
cells showed a 4–5 fold higher migration ability than the vehicle
control cells (Figure S2B) and a 7 fold higher invasion ability than
the vehicle control cells (Figure S2C). Taken together, these
findings support the hypothesis that FLJ10540 can promote cell
migration and invasion in mammalian cells.
Knock-down of endogenous FLJ10540 by siRNA
suppresses lung cancer cell migration and invasion
To confirm that FLJ10540 affects cell migration and invasion
in human lung cancer cells, we used a siRNA approach to inhibit
endogenous expression of FLJ10540 and then assayed the
migration and invasion abilities of CL1-5 and H1299 cells. First,
to examine the specificity of siRNAs, an HA-tagged FLJ10540
expression construct was co-transfected with three different
siRNAs; these consisted of two chemically synthesized siRNAs
specific for FLJ10540 (siFLJ10540-1 and siFLJ10540-2) and a
negative control siRNA, which were each transfected into
HEK293T cells. Both FLJ10540 siRNAs showed almost
complete inhibition of HA-tagged FLJ10540 expression, as
shown by western blot analysis using an anti-HA antibody,
while the level of HA-tagged FLJ10540 remained high with the
negative control siRNA (data not shown). Second, to examine if
the specific FLJ10540 siRNAs could inhibit endogenous
FLJ10540 expression in CL1-5 and H1299 cells, we transfected
siRNAs into CL1-5 and H1299 cells for 24 hours, followed by
western blot analysis using an antibody against FLJ10540. The
data showed a dramatic reduction in the FLJ10540 protein levels
with both FLJ10540 siRNAs, and there was no significant
reduction of FLJ10540 when the negative siRNA was used
(Figure 3A and B, left panel). However, the proliferation rate, as
determined by the MTT assay, was not significantly different
between the negative control cells and cells expressing FLJ10540
siRNAs during 24 hours (Figure 3A and B, middle panel). Third,
to study the effect of siRNA FLJ10540 transfection on migration,
negative control and siRNA FLJ10540-transfected CL1-5 or
H1299 cells were separately seeded on Transwell chambers with
uncoated filters. After 24 hour incubation, the motility potential
of siRNA FLJ10540 cells was found to have been strongly
inhibited by the siRNAs (Figure 3A and B, right panel). Finally,
the same panels of negative or FLJ10540 siRNA transfected cells
were seeded in a Matrigel-coated Transwell chamber. After
24 hours of incubation, the invasive potential of the siRNA
FLJ10540 cells appeared to be significantly reduced (Figure 3A
and B, right panel). These results strongly support the idea that
FLJ10540 plays a role in cell migration and invasion in human
lung cancer cells.
Using the concept of syn-expression to uncover VEGF-A,
but not VEGF-B, as the upstream regulator of FLJ10540
Genes belonging to the same pathway often show the same
expression profiles, which is referred to as syn-expression [27].
Hence, to map the potential signaling pathway or upstream
regulator(s) participating in FLJ10540-elicited migration and
invasion characteristics, we employed our lung cancer microarray
dataset, as described earlier, to gain insight into the functional
concordance of co-expressed genes. To test this hypothesis, we first
examined whether the mRNA expression profile of FLJ10540
correlates with any ligand or receptor in our lung cancer
microarray database (Figure 1). Of these co-expressed genes, the
top candidate is VEGF-A, which was highly positively correlated
with the mRNA expression level of FLJ10540 in paired lung
cancer patients (r=0.7 p,0.001) (Figure 4A). VEGF-A is known
to be a critical pro-angiogenic factor, with abilities to regulate
many steps in the angiogenic process, including proliferation,
migration, invasion, and survival [28,29]. In fact, VEGF-A is
highly expressed in many malignant tumors, including lung cancer
[30,31,32], and the expression of VEGF-A is associated with poor
prognosis [33,34] and the presence of lymph node metastasis [35],
raising the possibility that the biological roles of FLJ10540 and
VEGF-A might be functionally linked in lung adenocarcinoma.
Given the major role of VEGF-A in regulating migration and
invasiveness, we were first interested in whether VEGF-A could
modulate FLJ10540 protein expression. The results showed that
the protein expression level of FLJ10540 was upregulated in a
VEGF-A dose-dependent manner in CL1-0 lung cancer cells
(Figure 4B, left panel). We next asked whether the antagonistic
effect of SU5416, a VEGFR-2 tyrosine kinase inhibitor, on
biological activities of VEGF-A could be attributed to the
inhibition of FLJ10540 protein overexpression induced by
VEGF-A in lung cancer cells. The results demonstrated that
upregulation of FLJ10540 in the presence of VEGF-A was
inhibited by simultaneous addition of SU5416 in a dose-dependent
manner (Figure 4B, middle panel). On the contrary, the protein
level of FLJ10540 was not affected by treatment with VEGF-B
(Figure 4B, right panel). In fact, FLJ10540 does not share similar
expression patterns with VEGF-B, at least not in our lung cancer
microarray, supporting the idea that synexpression patterns could
be used to infer the function of unknown genes [27].
VEGF-A-induced FLJ10540 overexpression and
translocation enhances lung cancer cell migration and
invasion through an EMT-independent pathway
To test the biological significance of VEGF-A-induced upregu-
lation of FLJ10540, we examined the influence of FLJ10540 on
migration and invasion in the presence or absence of VEGF-A.
First, we examined whether parental CL1-0 cells could display cell
motility after stimulation by VEGF-A. In figure 4C, CL1-0 cells
exhibited more migration and invasive abilities in the presence of
VEGF-A alone than VEGF-A combined with SU5416 or vehicle
alone, suggesting that the addition of VEGF-A significantly
increased the migration and invasion of CL1-0 cells, which was
paralleled by an increase in FLJ10540 levels. Similar results were
found in FLJ10540 CL1-0-stable transfectants, with or without
VEGF-A stimulation (Figure 4D).
To test whether the subcellular localization of FLJ10540 could
be altered in lung cancer cells upon VEGF-A stimulation, we
adopted the indirect immunofluorescence approach to observe
FLJ10540 localization in CL1-0 lung cancer cells either with or
without VEGF-A stimulation. As shown in figure 4E, VEGF-A
treatment not only resulted in an increase in FLJ10540 protein
expression, but it also promoted the translocation of a fraction of
FLJ10540 to the cell membrane. In addition, the differences in cell
morphology were more apparent, highlighting the extension of
VEGF-A treated cells (Figure 4E, 30 min and 180 min) as
compared with the rounded CL1-0 cells (Figure 4E, 0 min). These
morphological changes prompted us to examine the phenomenon
of epithelial-mesenchymal transition (EMT). During tumorigene-
sis, EMT may increase the motility and invasiveness of cancer
cells, and malignant transformation may be associated with
signaling pathways promoting EMT [36]. A previous study also
indicated that extracellular signals induced by VEGF-A are
strongly implicated in EMT in human pancreatic carcinoma cells
[37]. To examine whether FLJ10540 might mediate VEGF-A-
VEGFA Upregulates FLJ10540
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used H1299 and CL1-0 lung cancer cells, with or without VEGF-A
stimulation, to address this question. However, despite increasing
cell motility by overexpressing FLJ10540 or decreasing cell
motility by FLJ10540-mediated siRNAs, differences in FLJ10540
levels did not in any way alter the expression levels of any of the
marker proteins associated with EMT, such as E-cadherin and
vimentin (data not shown). Therefore, FLJ10540 seems to mediate
migration and invasion effects of VEGF-A independently of EMT
and does not appear to play a role in the regulation of EMT, at
least in the lung cancer cell lines we analyzed.
A positive correlation in protein expression of FLJ10540/
VEGF-A and FLJ10540/AKT-p is observed in clinical
specimens of lung adenocarcinoma at variable stages
VEGF signals are partially tramitted through a PI3K-mediated
signaling cascade, which includes AKT [38], and FLJ10540 could
form a complex with PI3K in HCC [13]. These observations raise
the possibility that VEGF-A/FLJ10540/PI3K/AKT might be in
the same pathway, despite the fact that the gene expression
patterns of AKT in our lung cancer microarray dataset did not
exhibit any correlation with FLJ10540. This is not surprising,
because the activation state of the PI3K signaling pathway is
monitored by phosphorylated AKT. Therefore, we set up a tissue
microarray, containing 273 archived lung adenocarcinomas at
variable stages, to examine the protein expression patterns among
these molecules. The immunohistochemical studies of HE staining
(Figure 5A), VEGF-A (Figure 5B), FLJ10540 (Figure 5C), and
phosphorylated AKT (Figure 5D) were performed on these lung
adenocarcinoma specimens. The correlation between each paired
IHC score of AKT-p, VEGF, and FLJ10540 was analyzed by the
Spearman’s rank tests. The results showed that there were positive
correlations between VEGF and FLJ10540 (correlation coeffi-
cient=0.36, p,0.001) and AKT-p and FLJ10540 (correlation
coefficient=0.22, p=0.001). These results seem to imply that
FLJ10540 may participate in a VEGF-A-mediated PI3K/AKT
pathway in lung adenocarcinoma.
Activation of PI3K/AKT is critical for FLJ10540-induced
lung cancer cell migration and invasion upon VEGF-A
stimulating
Tumor cells possess a broad spectrum of migration and
invasion mechanisms that are associated with enhanced tumor
metastasis [4]. To explore how many signaling transduction
pathways might participate in FLJ10540-mediated cell migration
and invasion in lung cancer cells, we first investigated three well-
defined signaling pathways, namely the PI3K/AKT, p38, and
MAPK pathways, using pharmacological inhibitors. Figure 6A
and Figure S3A show that FLJ10540-CL1-0 and FLJ10540-
RK3E expressing cells had increased levels of cell migration and
invasion, which were strongly decreased by incubation with
LY294002, and to a much lesser extent, with SB202190 and
PD98059. The same was found when PI3K was inhibited with
wortmannin, a PI3K inhibitor (data not shown). Moreover,
Figure 3. The migration and invasion abilities of lung cancer cells are inhibited by FLJ10540-mediated siRNAs. (A and B, left panel) A
negative control siRNA with two different FLJ10540 siRNAs (siFLJ10540-1 and siFLJ10540-2) were transfected into CL1-5 and H1299 cells for 24 hours.
After transfection, western blotting was performed using anti-FLJ10540 and anti-b-actin antibodies. (A and B, middle panel) To measure cell growth
rates, 5610
3 cells of negative control-CL1-5,C L 1-5-FLJ10540 siRNAs, negative control-H1299, and H1299-FLJ10540 siRNAs were plated at day 0 in 96
well plates with 10% FBS. The cells were counted at indicated time points by the MTT assay (OD570) to quantify the cell growth. Data were normalized
against the OD570 value on day 0 of each treatment. The growth rate of CL1-5 and H1299 cells are shown as the mean6s.d. of three independent
experiments. (A and B, right panel) The migration relative-fold and the invasion relative-fold of CL1-5 and H1299 were normalized against negative
control cells and represented diagrammatically. The results represent the mean6s.d. of three independent experiments.
doi:10.1371/journal.pone.0005052.g003
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PLoS ONE | www.plosone.org 6 April 2009 | Volume 4 | Issue 4 | e5052Figure 4. VEGF-A promotes FLJ10540 protein expression and enhances FLJ10540-induced migration and invasion in lung cancer
cells. (A) The microarray expression patterns of VEGF-A and FLJ10540 in lung adenocarcinoma patients were shown. The results were normalized
against the expression patterns of 56 chips (HG_U133A). N: adjacent non-tumor tissues; T: tumor tissues. (B, left panel) VEGF-A induced an increase in
FLJ10540 protein levels in a dose-dependent manner. After treatment with various concentration of VEGF-A (left panel) or VEGF-B (right panel) for
10 min in CL1-0 cells, the total proteins were extracted from CL1-0 cells and probed with antibody against FLJ10540. (B, middle panel) Serum-starved
CL1-0 cells were pre-treated with or without various concentrations of SU5416 for 2 hours; cells were then stimulated with 20 ng/ml VEGF-A for
10 min. b-actin was used as an internal loading control. (C) Serum-starved CL1-0 cells were pre-treated with or without SU5416 for 2 hours; cells were
then stimulated with VEGF-A (at the concentration of 20 ng/ml) for 3 hours. The migration and invasion relative-folds were normalized against
vehicle cells. (D, left, upper panel) For the migration assay, 5610
3 cells of vehicle-CL1-0 and CL1-0-FLJ10540 stable clones were seeded into the top of a
Transwell insert and allowed to adhere for 12 hours, and were then incubated with or without VEGF-A (20 ng/ml) for 3 hours. At the end of the assay,
the cells on the topside were scraped, and the cells that migrated to the bottom were fixed and stained with Giemsa. (D, left, bottom panel) For the
invasion assay, 1610
4 cells were seeded after Matrigel was added, and were then incubated with or without VEGF-A (20 ng/ml) for 3 hours. All of the
data represent the mean6s.d. of three independent experiments. (E) Indirect immunofluorescence analysis of FLJ10540 in VEGF-A-treated cells. The
protein expression and the subcellular localization of FLJ10540 were analyzed in the presence or absence of VEGF-A (20 ng/ml) in CL1-0 cells using
immunofluorescence microscopy. After being incubated with or without VEGF-A for 30 min or 180 min, the cells were fixed with 3.7% formaldehyde
and processed for indirect immunofluorescence microscopy. FLJ10540 translocated to the cell membrane upon VEGF-A treatment (Arrowhead). Bar:
10 mm.
doi:10.1371/journal.pone.0005052.g004
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473 phosphorylation was observed in CL1-0-
FLJ10540 and RK3E-FLJ10540 cells, compared with vehicle
control cells, whereas FLJ10540-induced AKT-Ser
473 phosphor-
ylation was completely abolished by LY294002 (Figure 6B).
These results indicate that FLJ10540-induced cell migration and
invasion is mediated by the PI3K/AKT pathway.
We next investigated whether FLJ10540 might serve as a
critical mediator of VEGF-A-induced cell migration and
invasion. As Figure S3B shows, the FLJ10540-CL1-0 expressing
cells, either with or without VEGF-A stimulation, had higher
rates of cell migration and invasion, which were also strongly
decreased by incubation with LY294002, but not by SB202190
and PD98059. Next, we took two approaches to provide
additional evidence for the participation of AKT in FLJ10540-
elicited cell migration and invasion upon VEGF-A treatment.
First, we analyzed whether the increasing level of endogenous
AKT-Ser
473 phosphorylation could be observed in CL1-0-
FLJ10540 transfected cells upon VEGF-A stimulation. Our data
indicated that elevated AKT phosphorylation was observed in
CL1-0-FLJ10540 cells upon VEGF-A stimulation, compared with
the vehicle treated cells (Figure 6C). Furthermore, FLJ10540-
induced AKT-Ser
473 phosphorylation was completely abolished
by LY294002 upon VEGF-A stimulation (Figure 6C). Our
second goal was to examine if specific FLJ10540 siRNAs could
affect endogenous AKT activation in CL1-0 cells, with or without
VEGF-A stimulation. The data indicated that without VEGF-A
stimulation of FLJ10540-depleted cells, the activation of AKT
was greatly reduced compared to that seen in negative control
cells (Figure 6D, left panel). Compared with negative control
cells, the phosphorylated AKT levels were slightly increased upon
VEGF-A stimulation in FLJ10540-depleted cells (Figure 6D, right
panel), probably due to low residual FLJ10540 present in cells.
Taken together, these results indicated that FLJ10540 is required
for proper VEGF-A-dependent signaling and contributes to the
PI3K/AKT pathway.
VEGF-A-elicited FLJ0540 expression enhances the
physical association with the PI3K complex
It has been observed that upon VEGF-A stimulation, increased
levels of FLJ10540 can enhance AKT phosphorylation and that
FLJ10540 can form a complex with PI3K [13]. This raises the
possibility that increased levels of FLJ10540 could reinforce the
association between p110-a and p85-a. To test this hypothesis,
VEGF-A was used to treat CL1-0 lung cancer cells, either with or
without SU5416. Cell lysates were immunoprecipitated with anti-
p110-a antibody, and immuno-precipitates were analyzed by
immunoblotting with anti-FLJ10540 and anti-p85-a. Cells with
increased FLJ10540 levels, due to VEGF-A stimulation, had a
slightly enhanced amount of the FLJ10540/p110-a/p85-a com-
plex, as compared with cells without VEGF-A treatment
(Figure 6E, upper panel). However, the affinity of the
FLJ10540/p110-a/p85-a complex was decreased when cells were
treated with SU5416 alone or with SU5416 combined with
VEGF-A. To further confirm the association between the
FLJ10540-PI3K complexes, we used FLJ10540-mediated siRNAs
to address this question. Our data indicated that the degree of
physical association between p110-a and p85-a was significantly
decreased when endogenous FLJ10540 was depleted in CL1-0 lung
cancer cells (Figure 6E, lower panel). These data indicated that
increased FLJ10540, due to VEGF-A stimulation, may act as an
important scaffold protein that can enhance and stabilize the PI3K
complex in mammalian cells.
Discussion
Identification of key regulators from microarray datasets
remains a daunting task. Data integration and various bioinfor-
matics approaches may substantially facilitate unmasking of a
cryptic microarray dataset to identify targets and to dissect
underlying mechanisms. Here, we show that FLJ10540 is the
molecule interface between VEGF-A and the PI3K/AKT
pathway. PI3K/AKT signal transduction has been shown to be
a crucial element leading to survival, proliferation, migration, and
invasion of human cells induced by VEGF-A [39]. Several reports
have shown that the VEGF-A/VEGFR-mediated PI3K/AKT
pathway is associated with signaling intermediates, such as
phospholipase C-c, GTPase-activating protein, Grb2-Gab1, and
Shp2-Gab1 [29,40,41]. These interactions, including several
PI3K-interacting partners, result in tyrosine phosphorylation of
some of the potential substrates. However, the functional
significance between PI3K-associated proteins and PI3K/AKT
activation in VEGF-A signaling in lung adenocarcinomas has not
been defined clearly. Here, our results show for the first time that
FLJ10540 not only forms and stabilizes the PI3K complex upon
VEGF-A stimulation, but also contributes to cell migration and
invasion following PI3K/AKT activation in lung cancer cells. Our
findings unravel a long unanswered question, finally demonstrat-
ing that FLJ10540 is the missing factor that bridges the activation
mechanism of PI3K/AKT upon VEGF-A stimulation in cancer
cells. Moreover, further studies are warranted to investigate
whether FLJ10540, translocated from the cytoplasm to the plasma
membrane after stimulation by VEGF-A, could interact with
VEGFR or VEGFR-associated proteins directly or indirectly,
prompting PI3K/AKT activation or participating in other
pathways.
Various evidence points to the importance of deregulated
PI3K/AKT signaling in lung cancer. Overexpression of both, the
regulatory p85-a and the catalytic p110-a subunits of PI3K, was
reported in primary human lung carcinomas [42,43]. Genomic
amplification of the PIK3CA (p110-a) gene was also documented in
Figure 5. Histopathologic and immunophenotypic findings in
lung adenocarcinomas with immunoreactivity for VEGF-A,
FLJ10540, and phosphorylated AKT. (A) The tumor has a papillary
growth pattern (Hematoxylin & Eosin, 1006). (B) The tumor cells are
immunoreactive with VEGF-A, with a staining intensity score of 2
(1006). (C) The tumor cells are immunoreactive with FLJ10540, with a
staining intensity score of 2 (1006). (D) The tumor cells are
immunoreactive with phosphorylated AKT, with a staining intensity
score of 3 (1006).
doi:10.1371/journal.pone.0005052.g005
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PLoS ONE | www.plosone.org 8 April 2009 | Volume 4 | Issue 4 | e5052Figure 6. FLJ10540 alone or increased FLJ10540, mediated by VEGF-A stimulation, not only modulates cell migration and invasion
through the PI3K/AKT signaling pathway, but also reinforces PI3K complex formation. (A) Vehicle-CL1-0,C L 1-0-FLJ10540, vehicle-RK3E, and
RK3E-FLJ10540 infected cells were serum-starved for 24 hours and treated with or without the indicated inhibitors, including SB202190, PD98059,
and LY294002 for 2 hours. The migration and invasion ratios of vehicle-CL1-0,C L 1-0-HA-FLJ10540, vehicle-RK3E, and RK3E-Flag-FLJ10540 infected cells
were determined as previously described. (B) CL1-0 and RK3E-expressing FLJ10540 cells were treated with or without LY294002 at the final
concentration of 10 mM. The total cell lysates were subjected to immunoblot analysis for the unphosphorylated or phosphorylated form of AKT. b-
actin was used as an internal loading control. (C) CL1-0 cells expressing HA-FLJ10540 were pre-treated with or without VEGF-A (20 ng/ml). After
10 min, LY294002 (10 mM) was added and cells were further incubated for 2 hours. The total cell lysates were subjected to immunoblot analysis for
HA, FLJ10540, or the unphosphorylated or phosphorylated forms of AKT. (D) A negative control siRNA and two different FLJ10540 siRNAs (siFLJ10540-
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implicating the PI3K/AKT pathway in lung cancer development
[44]. Several groups have reported that amplification, mutation,
and high levels of phosphorylated AKT in tumor tissues from lung
cancer patients correlated with poor prognosis in lung cancer
patients in stage I of the disease or with primary tumors
[42,44,45,46,47]. Moreover, in a panel of lung cancer cell lines,
PI3K-dependent AKT phosphorylation and activation of PI3K
also correlated with resistance to chemotherapy and radiotherapy
[48,49]. In short, inhibition of PI3K/AKT activation and
disruption of the associated proteins that enhance PI3K complex
formation have been widely proposed to represent promising
therapeutic approaches for treatment of lung cancer.
In summary, the explosion in microarray studies has promised
to shed light on potential disease markers and drug targets. This
study illustrates that FLJ10540 is highly expressed in human lung
adenocarcinomas, as well as in invasive lung cancer cell lines. This
abnormal expression of FLJ10540 in mammalian cells is able to
enhance cell migration and invasion. Moreover, the quantity of
FLJ10540 in cells could serve as a critical mediator of VEGF-A-
dependent biological events through activation of the PI3K/AKT
signaling pathway, resulting in the progression of lung adenocar-
cinoma. In short, FLJ10540 could represent a potential target for
the development of novel therapies for this widespread type of
cancer.
Materials and Methods
Patients and tumor samples
A total of 56 samples from our previous study [50] were used for
microarray analysis. These include pairwise samples from 26
patients, who underwent surgery for lung cancer at the Taipei
Veterans General Hospital, and 4 lung cancer cell lines CL1-0,
CL1-1,C L 1-5 [51] and CL1-5-F4 [52]. The data have been
deposited in NCBIs Gene Expression Omnibus (GEO) and are
accessible through GEO series accession number GSE7670. No
patients had previously received any neoadjuvant treatment, e.g.
chemotherapy, before the surgery. The study protocol had the
approval of the ethics committee at Taipei Veterans General
Hospital. All patients gave informed consents and signed the
consent form individually. Study samples, including tumor and
adjacent normal tissues, were obtained during diagnostic biopsy,
and adjacent normal tissues were derived from neighboring site
outside of the tumor. Both tumor and adjacent non-tumor tissues
for subsequent Q-RT-PCR studies were confirmed by patholo-
gists.
Quantitative reverse-transcription polymerase chain
reaction (Q-RT-PCR)
To confirm the microarray data for FLJ10540, 16-pairs tumor
and adjacent non-tumor tissues of lung patients’ samples were used
to validate the mRNA expression level of FLJ10540 by using Q-
RT-PCR, which was performed using a Taq-Man probe (ABI).
Data were represented as mean6s.d. To analyze the distribution
of tumor and adjacent non-tumor parts we performed the
Wilcoxon signed rank test between two groups for statistical
analysis. A P value of less than 0.05 was significant. GAPDH (ABI)
was used as an internal control for comparison and normalization
the data. Assays were performed in triplicate using Applied
Biosystems Model 7700 instruments.
Preparation of retroviral stock and infection
Retroviral vector-derived plasmid (1 mg) was introduced into
10
6 DF-1 cells by FuGENE 6 as described previously [53]. Viral
supernatant produced from these cells were harvested. For viral
infection, actively dividing RK3E/tv-a-expressing cells or control
cells were seeded. The next day, cells grown in fresh growth
medium were mixed with viral supernatant to a total volume of
2.5 ml for 60 mm-plate and incubated at 37uCi n5 %C O 2
incubator for one hour. Afterwards, fresh growth medium was
then added to the cell/virus mixtures.
Cell culture, transient transfection and establishment of
stable clones
All cell culture related reagents were purchased from Gibco-BRL.
MDCK(clone3B5)andRK3EcellsweregrowninDMEMmedium
containing 10% heat-inactivated FBS, 100 unit/ml penicillin and
streptomycin (Gibco-BRL). CL1-0,C L 1-5 and H1299 cells were
grown in RPMI medium containing 10% heat-inactivated FBS, 100
unit/ml penicillin and streptomycin (Gibco-BRL). Transient
transfection of HA-tagged FLJ10540 to CL1-0 was performed with
Lipofectamine
TM (Gibco-BRL) according to the manufacturer’s
instructions,whereasRK3E cells wereinfected with adenoviral Flag-
tagged FLJ10540. CL1-0 cells stably expressing constructs were
selected with 800 mg/ml G418 (Calbiochem). Individual clone was
picked up and analyzed for exogenous FLJ10540 expression by
western blotting. Each selected stable clones was lysed with
extraction buffer as described below. Two double-stranded synthetic
RNA oligomers (Ambion) (59-GGGAGAAATTGCACACTTA-39
and 59-GGACTTTTAGCAAAGATCT-39), deduced from human
FLJ10540, and one Silencer negative control #4611G siRNA
(Ambion) were used for siRNA experiments.
Preparation of cell extracts, immunoprecipitation and
western blot analysis
Cell-free lysates were prepared as described earlier [54]. Briefly,
cells were harvested,washed with PBS,and lysed inextraction buffer
(20 mM PIPES, pH 7.2, 100 mM NaCl, 1 mM EDTA, 0.1%
CHAPS, 10% sucrose, 1 mM dithiothreitol, 1 mM phenylmethyl-
sulfonyl fluorid (PMSF) and 1 mM Na3VO4,). For immunoprecip-
itation,1 mgoftotalcelllysatewasincubated withantibodiesagainst
target proteinsand Protein A/G-agarose beads(OncogeneResearch
Product) to immunoprecipitate the target protein. Antibody against
FLJ10540 (Abnova), AKT, AKT
473-p (Cell Signaling), Flag (Sigma),
HA (3F10, Roche), p110-a (Santa Cruz), p85-a (Santa Cruz) and b-
actin (Sigma) were incubated with the membrane at room
temperature for 1 h.The resulting IgGsweredetected byincubation
with secondary antibodies conjugated to HRP, and developed using
the Western Lighting reagent.
1 and siFLJ10540-2) were transfected into CL1-0 cells for 24 hours. After transfection, cells were treated with or without VEGF-A (20 ng/ml) for 10 min.
Western blotting was performed as in (C). (E upper panel) Serum-starved CL1-0 cells were pre-treated with or without SU5416 for 2 hours; cells were
then stimulated with or without 20 ng/ml VEGF-A for 10 min. Cell lysates were immunoprecipitated with polyclonal antibodies against p110-a or
protein IgG (as a control), which was followed by immunoblotting with p110-a, p85-a, and FLJ10540. (E lower panel) A negative control siRNA and
two different FLJ10540 siRNAs (siFLJ10540-1 and siFLJ10540-2) were transfected into CL1-0 cells for 24 hours. After transfection, cell lysates were
immunoprecipitated with polyclonal antibodies against p110-a, p85-a, or protein IgG (as a control), followed by immunoblotting with p110-a, p85-a,
and FLJ10540.
doi:10.1371/journal.pone.0005052.g006
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Vehicle-CL1-0, FLJ10540-CL1-0 stable clones, vehicle-negative
control and siRNAs FLJ10540 transfected cells of CL1-5 or H1299
(5610
3 ) were seeded in 96-well plates in RPMI containing 10%
FBS for 24 h followed by MTT assay to quantify the cell growth.
Data were normalized against OD570 value on day 0 of each
vehicle control.
Migration and Invasion Assay
The migration and invasion assays of the CL1-0 stable clones or
the RK3E infected cells were evaluated using a 24-well Transwell
(8-mm pore size polycarbonate membrane, Costar) chambers. For
the migration assay, 5610
3 CL1-0 stable clones were suspended in
400 ml of DMEM or RPMI containing 10% FBS and were seeded
into the upper chamber, while 600 ml of DMEM or RPMI
containing 10% FBS was added to the outer side of the chamber.
After being cultured in a 37uC, 5% CO2/95% air environment
and allowed to adhere for 12 hours and then incubated with or
without VEGF-A (20 ng/ml) for 10 min, cells on the upper surface
of the membrane were removed by a cotton tip applicator and
migratory cells on the lower membrane surface were fixed by
methanol and stained with Giemsa (Sigma). Cell migration values
were determined by counting from three independent membranes
and then normalized using vehicle cells to give a relative ratio. For
invasion assay, 80 mg/ml of Matrigel (BD Bioscience) was added
to the upper surface of the membrane and allowed for gelling at
37uC for overnight. Cells (1610
4) in 400 ml of DMEM containing
10% FBS were seeded to the upper chamber, and 600 mlo f
DMEM containing 10% FBS was added to the outer side of the
chamber. The rest of procedures for invasion assay were the same
as in the migration assay.
Tissue Microarray Analysis
Tissue cores manually removed from 273 archived lung
adenocarcinomas were inserted into paraffin blocks to generate
tissue arrays. The population includes 153 male and 120 female
patients, with variable pathological stages (stage IA, 45 patients;
IB, 105; IIA, 5; IIB, 18; IIIA, 49; IIIB, 21; IV, 12). Sections 5 mm
in thickness were obtained and mounted on positively charged
slides for immunohistochemical studies.
Immunohistochemistry
Immunohistochemical detection of protein expression is per-
formed on formalin-fixed, paraffin-embedded tissue sections of lung
adenocarcinoma tissue arrays with standard procedures. The tissue
sectionswereincubatedat4uCovernightwithprimaryantibodiesfor
VEGF-A (1:800 dilution, BioGenex, sc-152), FLJ10540 (1:800
dilution) and AKT
473-p (1:100 dilution). The intensities of the
immunohistochemical staining were scored based on the following
criteria: no or minimal staining in ,10% of the tumor cells, score 0;
faint, barely visible staining in .10% of the tumor cells, score 1;
weak to moderate staining in .10% of the tumor cells, score 2;
strong staining in .10% of the tumor cells, score 3.
Statistical analyses
The correlation between each paired IHC scores of AKT
473-p,
VEGF and FLJ10540 were analyzed by Spearman’s rank tests. A p
value ,0.05 was considered statistically significant. All analyses
were carried out using statistics software SPSS 12.0 edition.
Immunofluorescence microscopy
CL1-0 cells were incubated with VEGF (20 ng/ml) for 30 min
or 180 min, the cells were washed with PBS and fixed with 3.7%
formaldehyde in PBS for 15 min at 25uC. Cells on the coverslips
were blocked with 5% BSA (Sigma) in PBS. The fixed cells were
probed with anti-FLJ10540 antibody (1:400) for 12 hrs at 4uC and
then washed three times with 0.1% Triton X-100 in PBS.
Immunofluorescent cell images were acquired using an Olympus
Fluoview FV1000 Confocal laser scanning microscope (Olympus).
Images were processed with Adobe Photoshop software (Adobe
Systems). All data were collected during the same session to avoid
potential differences due to fading.
Supporting Information
Figure S1 Oncology. Molecular portraits of lung adenocarcino-
ma. (A) Supervised hierarchical clustering showed the 826 (634
down- and 192 up-regulated) transcript expression patterns of 26-
pairwise lung adenocarcinoma samples. The results were shown in
a dendrogram format, in which rows represent individual
transcripts and columns represent tissue samples. Especially,
FLJ10540 was shown in one of 192 up-regulated transcripts.
The color in each cell reflected the expression level of the
corresponding tissue, relative to its median expression level. The
scale extends from fluorescence ratios of 0.25 to 4 relative to the
median level for all samples. (B) The mRNA expression level of
FLJ10540 was determined by Q-RT-PCR in 16 lung cancer
patients. Overexpression of FLJ10540 was observed in 15 out of
16 lung cancer patient samples. The results were normalized
against the expression level of GAPDH mRNA in each sample.
Found at: doi:10.1371/journal.pone.0005052.s001 (8.38 MB TIF)
Figure S2 Oncology. FLJ10540 overexpression enhances motil-
ity of RK3E cells. (A) FLJ10540 stable clones of retrovirus infected
Flag-tagged FLJ10540 in RK3E cells was established. The cell
lysates were subjected to immunoblot analysis with anti-Flag
antibody. (B) For the migration assay, 56103 cells of vehicle-
RK3E and RK3E-FLJ10540 infected cells were seeded into the
top of a Transwell insert. After 24 hours, the cells on the topside
were scraped, and the cells that migrated to the bottom were fixed
and stained with Giemsa. The migration photography results of
vehicle-RK3E and RK3E-FLJ10540 infected cells are shown
(2006). The migration relative-folds of vehicle-RK3E and RK3E-
FLJ10540 infected cells were normalized with vehicle control and
presented diagrammatically. (C) For the invasion assay, 16104
cells were seeded after Matrigel was added. The invasion
photography results of vehicle-RK3E and RK3E-FLJ10540
infected cells are shown (2006). The invasion relative-folds of
stable clone and infected cells were normalized against vehicle cells
and represented diagrammatically. All of the data represent the
mean6s.d. of three independent experiments.
Found at: doi:10.1371/journal.pone.0005052.s002 (9.12 MB TIF)
Figure S3 Oncology. FLJ10540 mediates cell migration and
invasion through the PI3K/AKT signaling pathway. (A). The
migration and invasion photography results of vehicle-CL1-0,
CL1-0-FLJ10540 stable clones, vehicle-RK3E and RK3E-
FLJ10540 infected cells were treated with or without LY294002
at the final concentration of 10 mM are shown (2006). The data
represent the mean6s.d. of three independent experiments. (B)
Vehicle-CL1-0 and CL1-0-FLJ10540 stable clones on the
Transwell insert were serum-starved for 24 hours and treated
with or without the indicated inhibitors for 2 hours. Cells were
then stimulated with or without VEGF-A at the final concentra-
tion at 20 ng/ml for 10 min. The migration and invasion ratios of
vehicle-CL1-0 and CL1-0-FLJ10540 stable clones were deter-
mined. The data represent the mean6s.d. of three independent
experiments.
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